Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Liabilities and Shareholders Equity: 2016-2024

Historic Liabilities and Shareholders Equity for UroGen Pharma (URGN) over the last 9 years, with Dec 2024 value amounting to $285.7 million.

  • UroGen Pharma's Liabilities and Shareholders Equity fell 38.71% to $185.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $927.1 million, marking a year-over-year decrease of 3.70%. This contributed to the annual value of $285.7 million for FY2024, which is 60.23% up from last year.
  • UroGen Pharma's Liabilities and Shareholders Equity amounted to $285.7 million in FY2024, which was up 60.23% from $178.3 million recorded in FY2023.
  • UroGen Pharma's 5-year Liabilities and Shareholders Equity high stood at $285.7 million for FY2024, and its period low was $119.7 million during FY2021.
  • Over the past 3 years, UroGen Pharma's median Liabilities and Shareholders Equity value was $178.3 million (recorded in 2023), while the average stood at $199.9 million.
  • As far as peak fluctuations go, UroGen Pharma's Liabilities and Shareholders Equity tumbled by 39.72% in 2020, and later soared by 60.23% in 2024.
  • Over the past 5 years, UroGen Pharma's Liabilities and Shareholders Equity (Yearly) stood at $122.0 million in 2020, then declined by 1.85% to $119.7 million in 2021, then climbed by 13.26% to $135.6 million in 2022, then surged by 31.48% to $178.3 million in 2023, then spiked by 60.23% to $285.7 million in 2024.